Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 001 - AKSO Biopharmaceutical

Next Previous
X
Search
Drug Profile

AB 001 - AKSO Biopharmaceutical

Alternative Names: AB-001 - AKSO Biopharmaceuticals

Latest Information Update: 01 Aug 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AKSO Biopharmaceutical
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action B cell activating factor inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; IgA nephropathy; Immunological disorders

Most Recent Events

  • 27 Jul 2022 Pharmacodynamics data from a preclinical study in Multiple myeloma and Diffuse large B cell lymphoma released by AKSO Biopharmaceutical
  • 22 Mar 2022 Preclinical trials in Haematological malignancies in USA (Parenteral) (AKSO Biopharmaceutical pipeline, March 2022)
  • 22 Mar 2022 Preclinical trials in IgA nephropathy in USA (Parenteral) (AKSO Biopharmaceutical pipeline, March 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top